Last reviewed · How we verify
NCT07094022
Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia
NA trial testing Nutrilite Protein MetX Pro in Dyslipidemia in 66 participants. Completed in 3 June 2025.
3 June 2025
Quick facts
| Lead sponsor | Amway (China) R&D Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 66 |
| Start date | 16 March 2025 |
| Primary completion | 3 June 2025 |
| Estimated completion | 3 June 2025 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Nutrilite Protein MetX Pro
- Placebo Product
Conditions studied
- Dyslipidemia — all drugs for Dyslipidemia →
- Obesity &Amp; Overweight — all drugs for Obesity &Amp; Overweight →
Sponsor
Amway (China) R&D Center
Who can join
Adults 18 to 65, any sex, with Dyslipidemia or Obesity &Amp; Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized, double-blind, placebo-controlled, single center study is to evaluate the impact of Nutrilite Protein MetX Pro (the study product, a high-protein compound beverages supplemented with multiple plant proteins and apple extracts) on lipid profiles in the blood test in overweight individuals with dyslipidemia. The main question it aims to answer is: \- Does the intake of the study product improve the blood lipid profiles (TC,TG, LDL-C ) in terms of of overweight individuals with dyslipidemia? Researchers will compare the product group to a placebo group to see whether the blood lipid profile is significantly better improved for participants in the product group. Participants will: * take randomly assigned products 16g/each time, twice a day for 4 weeks * make four times site visits, once a week. Blood samples are collected for each visit, and Feces are collected for the first and last site visit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07094022
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dyslipidemia
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
- NCT06919302 — The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care. · NA · recruiting
- NCT07162441 — A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and · Phase 1 · recruiting
- NCT07043166 — Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens · recruiting
Other Amway (China) R&D Center trials
Trials by the same sponsor.
- NCT07161557 — Evaluating Metabolic Health in People Aged 18 to 60 by Nutrilite Metabolic Health Index · not yet recruiting
- NCT06499012 — The Efficacy of Nutrilite All-plant Protein Booster to Improve Sarcopenia and Osteoarthritis in Middle-aged and Elderly · NA · completed
- NCT06084585 — The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia · NA · unknown
- NCT05986799 — The Efficacy of Amway Herbal Drink to Improve Skin Anti-aging · NA · unknown
- NCT05872360 — To Investigate Effects of Amway Bundle Combination of Products on Osteoarthritis & Sarcopenia · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07094022 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amway (China) R&D Center
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07094022.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing